Characteristics of analyzed patients and pretreatment TCR-Vβ spectratype results
| UPN . | Age/sex . | FAB type . | Clinical response* . | No. of pretreatment skewed TCR-Vβ families . |
|---|---|---|---|---|
| 1 | 63/M | RARS | Yes | 1 |
| 2 | 71/M | RA | Yes | 3 |
| 3 | 55/F | RA | Yes | 11 |
| 4 | 44/M | RA | No | 11 |
| 5 | 45/M | RA | Yes | 5 |
| 6 | 27/M | RA | No | 2 |
| 7 | 78/M | RAEB | No | 6 |
| 8 | 70/M | RAEBt | No | 15 |
| 9 | 73/F | RAEBt | No | 2 |
| 10 | 70/F | RAEB | No | 9 |
| 11 | 61/F | RAEB | No | 17 |
| 12 | 44/F | RARS | No | 10 |
| UPN . | Age/sex . | FAB type . | Clinical response* . | No. of pretreatment skewed TCR-Vβ families . |
|---|---|---|---|---|
| 1 | 63/M | RARS | Yes | 1 |
| 2 | 71/M | RA | Yes | 3 |
| 3 | 55/F | RA | Yes | 11 |
| 4 | 44/M | RA | No | 11 |
| 5 | 45/M | RA | Yes | 5 |
| 6 | 27/M | RA | No | 2 |
| 7 | 78/M | RAEB | No | 6 |
| 8 | 70/M | RAEBt | No | 15 |
| 9 | 73/F | RAEBt | No | 2 |
| 10 | 70/F | RAEB | No | 9 |
| 11 | 61/F | RAEB | No | 17 |
| 12 | 44/F | RARS | No | 10 |
UPN indicates unique patient number; FAB, French-American-British.
Clinical response means that effective hematopoiesis was restored after ATG-based treatment, as determined by transfusion independence and improvement in cytopenia.